Royalty Pharma plc Proceeds from Sale and Maturity of Marketable Securities
Royalty Pharma plc (RPRX) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-02-11
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $0.00.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for fiscal 2025 was $0.00.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for fiscal 2023 was $24.39M, a 96.92% decline from fiscal 2022.
- Royalty Pharma plc proceeds from sale and maturity of marketable securities for fiscal 2022 was $792.34M, a 50.41% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 6 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-11 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $24.39M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $24.39M 10-Q · filed 2024-11-06 | $140.03M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $24.39M 10-Q · filed 2024-08-08 | $140.03M derived: sum of 3 quarters · filed 2025-02-12 | $290.82M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $24.39M 10-Q · filed 2024-05-09 | $140.03M derived: sum of 2 quarters · filed 2025-02-12 | $290.82M derived: sum of 3 quarters · filed 2025-02-12 | $542.12M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $115.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $266.43M derived: sum of 2 quarters · filed 2025-02-12 | $517.73M derived: sum of 3 quarters · filed 2025-02-12 | $792.34M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $150.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $402.10M derived: sum of 2 quarters · filed 2023-11-08 | $676.71M 10-Q · filed 2023-11-08 | $781.42M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $251.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $525.91M 10-Q · filed 2023-08-08 | $630.62M derived: sum of 3 quarters · filed 2024-02-15 | $1.26B derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | $274.61M 10-Q · filed 2023-05-09 | $379.32M derived: sum of 2 quarters · filed 2024-02-15 | $1.00B derived: sum of 3 quarters · filed 2024-02-15 | $1.45B derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $104.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $729.16M derived: sum of 2 quarters · filed 2024-02-15 | $1.18B derived: sum of 3 quarters · filed 2024-02-15 | $1.60B 10-K · filed 2024-02-15 | |
| 2021-09-30 | $624.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.07B derived: sum of 2 quarters · filed 2022-11-08 | $1.49B 10-Q · filed 2022-11-08 | $1.70B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | $448.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $868.69M 10-Q · filed 2022-08-04 | $1.07B derived: sum of 3 quarters · filed 2023-02-15 | $1.35B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | $419.78M 10-Q · filed 2022-05-05 | $625.62M derived: sum of 2 quarters · filed 2023-02-15 | $899.21M derived: sum of 3 quarters · filed 2023-02-15 | $1.13B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2020-12-31 | $205.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $479.43M derived: sum of 2 quarters · filed 2023-02-15 | $710.83M derived: sum of 3 quarters · filed 2023-02-15 | $815.44M 10-K · filed 2023-02-15 | |
| 2020-09-30 | $273.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $504.99M derived: sum of 2 quarters · filed 2021-11-10 | $609.60M 10-Q · filed 2021-11-10 | $1.17B derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | $231.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $336.01M 10-Q · filed 2021-08-11 | $353.72M 10-Q · filed 2020-08-12 | $899.55M derived: sum of 3 quarters · filed 2022-02-15 | $1.06B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $104.61M 10-Q · filed 2021-05-11 | $668.15M derived: sum of 2 quarters · filed 2022-02-15 | $829.68M derived: sum of 3 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $563.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $725.07M derived: sum of 2 quarters · filed 2022-02-15 | $725.07M 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $161.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $161.53M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |